Other side of rock bottom

Well its good see Anp finally up and about. Should be a big year with multiple inflection points due.
Obviously the licensing of 1103 in the short term is providing the main impetus right now.
But looking ahead at potential 1102 deal and funding for a stage 2b with ind app will be a bigger deal providing they can nail it.
Not sure about further drug acquisitions would prefer them to be successful with the ones they have after mulling around for 15 years.
Anyway heres hoping in 2017 this thing finally gets some traction and the Board and its new members can finally prove themselves.